Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?

Publisher： Karger

E-ISSN： 1423-0232|77|3-4|217-223

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.3-4, 2009-09, pp. : 217-223

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine: Progress in the Treatment of Pancreatic Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 8-18

Karger

Access to resources Recommend Favorite

Sustained Partial Remission of Metastatic Pancreatic Cancer Following Systemic Chemotherapy with Gemcitabine and Oxaliplatin plus Adjunctive Treatment with Mistletoe Extract

By  

Oncology Research and Treatment, Vol. 33, Iss. 11, 2010-10 ,pp. : 617-619

Karger

Access to resources Recommend Favorite

Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 2, 2015-01 ,pp. : 142-145

Bentham Science Publishers

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?

By  

Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. : 462-467

Karger

Access to resources Recommend Favorite